Oppenheimer Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $132

Oppenheimer maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $115 to $132.

Benzinga · 01/13/2020 14:10

Oppenheimer maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $115 to $132.